BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37548686)

  • 1. THE EFFICACY AND SAFETY OF VASOPRESSORS FOR SEPTIC SHOCK PATIENTS: A SYSTEMIC REVIEW AND NETWORK META-ANALYSIS.
    Jia L; Wang P; Li C; Xie J
    Shock; 2023 Dec; 60(6):746-752. PubMed ID: 37548686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy of vasoactive medications in patients with septic shock: a network meta-analysis of randomized controlled trials.
    Cheng L; Yan J; Han S; Chen Q; Chen M; Jiang H; Lu J
    Crit Care; 2019 May; 23(1):168. PubMed ID: 31088524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-Analysis.
    Avni T; Lador A; Lev S; Leibovici L; Paul M; Grossman A
    PLoS One; 2015; 10(8):e0129305. PubMed ID: 26237037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of vasoactive drugs on mortality in patients with severe sepsis and septic shock. A network meta-analysis of randomized trials.
    Belletti A; Benedetto U; Biondi-Zoccai G; Leggieri C; Silvani P; Angelini GD; Zangrillo A; Landoni G
    J Crit Care; 2017 Feb; 37():91-98. PubMed ID: 27660923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasopressor therapy in critically ill patients with shock.
    Russell JA
    Intensive Care Med; 2019 Nov; 45(11):1503-1517. PubMed ID: 31646370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasopressor Therapy in the Intensive Care Unit.
    Russell JA; Gordon AC; Williams MD; Boyd JH; Walley KR; Kissoon N
    Semin Respir Crit Care Med; 2021 Feb; 42(1):59-77. PubMed ID: 32820475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Days alive and free as an alternative to a mortality outcome in pivotal vasopressor and septic shock trials.
    Russell JA; Lee T; Singer J; De Backer D; Annane D
    J Crit Care; 2018 Oct; 47():333-337. PubMed ID: 29958734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination era, using combined vasopressors showed benefits in treating septic shock patients: a network meta-analysis of randomized controlled trials.
    Chen C; Pang L; Wang Y; Wen T; Yu W; Yue X; Rong Y; Liao W
    Ann Transl Med; 2019 Oct; 7(20):535. PubMed ID: 31807517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials.
    Serpa Neto A; Nassar AP; Cardoso SO; Manetta JA; Pereira VG; Espósito DC; Damasceno MC; Russell JA
    Crit Care; 2012 Aug; 16(4):R154. PubMed ID: 22889256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasoactive drugs in the intensive care unit.
    Holmes CL
    Curr Opin Crit Care; 2005 Oct; 11(5):413-7. PubMed ID: 16175026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality benefit of vasopressor and inotropic agents in septic shock: a Bayesian network meta-analysis of randomized controlled trials.
    Oba Y; Lone NA
    J Crit Care; 2014 Oct; 29(5):706-10. PubMed ID: 24857641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasopressors for shock.
    Müllner M; Urbanek B; Havel C; Losert H; Waechter F; Gamper G
    Cochrane Database Syst Rev; 2004; (3):CD003709. PubMed ID: 15266497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodynamic Instability Secondary to Vasopressin Withdrawal in Septic Shock.
    Bissell BD; Magee C; Moran P; Bastin MLT; Flannery AH
    J Intensive Care Med; 2019 Sep; 34(9):761-765. PubMed ID: 28750598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock.
    Patel GP; Grahe JS; Sperry M; Singla S; Elpern E; Lateef O; Balk RA
    Shock; 2010 Apr; 33(4):375-80. PubMed ID: 19851126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial.
    Annane D; Vignon P; Renault A; Bollaert PE; Charpentier C; Martin C; Troché G; Ricard JD; Nitenberg G; Papazian L; Azoulay E; Bellissant E;
    Lancet; 2007 Aug; 370(9588):676-84. PubMed ID: 17720019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Norepinephrine vs Vasopressin: Which Vasopressor Should Be Discontinued First in Septic Shock? A Meta-Analysis.
    Wu Z; Zhang S; Xu J; Xie J; Huang L; Huang Y; Yang Y; Qiu H
    Shock; 2020 Jan; 53(1):50-57. PubMed ID: 31008869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Continuous Epinephrine Infusion on Survival in Critically Ill Patients: A Meta-Analysis of Randomized Trials.
    Belletti A; Nagy A; Sartorelli M; Mucchetti M; Putzu A; Sartini C; Morselli F; De Domenico P; Zangrillo A; Landoni G; Lembo R
    Crit Care Med; 2020 Mar; 48(3):398-405. PubMed ID: 31789701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Terlipressin for the treatment of septic shock in adults: a systematic review and meta-analysis.
    Huang L; Zhang S; Chang W; Xia F; Liu S; Yang Y; Qiu H
    BMC Anesthesiol; 2020 Mar; 20(1):58. PubMed ID: 32138657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study.
    Morelli A; Ertmer C; Rehberg S; Lange M; Orecchioni A; Cecchini V; Bachetoni A; D'Alessandro M; Van Aken H; Pietropaoli P; Westphal M
    Crit Care; 2009; 13(4):R130. PubMed ID: 19664253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Norepinephrine or dopamine for septic shock: systematic review of randomized clinical trials.
    Vasu TS; Cavallazzi R; Hirani A; Kaplan G; Leiby B; Marik PE
    J Intensive Care Med; 2012; 27(3):172-8. PubMed ID: 21436167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.